Cost Minimization Analysis of Antihypertensive Drugs Lisinopril or Candesartan in Hypertension Patients with Chronic Kidney Disease at The Inpatient Installation of RSUD Dr. H. Abdul Moeloek
Article Sidebar
Main Article Content
Abstract
Hypertension can damage blood vessels, which if not handled properly can cause kidney damage. Chronic Kidney Disease (CKD) is the most common comorbid in hypertensive patients in Indonesia with a percentage of 51%. The successful treatment of hypertension accompanied by CKD can be supported by administration of antihypertensives. The variety of antihypertensive therapy alternatives makes pharmacoeconomic studies necessary in order to obtain cost-effective therapy. The purpose of this study was to find out which antihypertensive drug is the most cost-minimizing between lisinopril and candesartan used in the treatment of hypertension accompanied by CKD (ICD-10 I12.0) in the Inpatient Installation based on the perspective of RSUD Dr. H. Abdul Moeloek in 2022. This research is a non-experimental observational with a purposive sampling technique. Data collection was carried out retrospectively from tracking secondary data originating from medical records, drug details in the Hospital Information System (SIRS), and details of direct medical costs in the Hospital Finance Department. Costs collected are in the form of direct medical costs which include antihypertensive drug costs, supporting drug costs, accompanying drug costs, laboratory costs, ICU, emergency room, hemodialysis, and hospitalization. The study showed that the average total cost of treating antihypertensive therapy for lisinopril was higher than candes artan, with lisinopril amounting to Rp 3.778.163 while candesartan was Rp 3.307.740. These results indicate that use of the antihypertensive candesartan is more cost-minimizing compared to lisinopril with a saving value of IDR Rp 470.423.
Keywords: Pharmacoeconomics; CMA; hypertension with CKD; lisinopril; candesartan
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish in PharmaCine: Journal of Pharmacy, Medical and Health Science agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-ShareAlike 4.0 International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
PharmaCine : Journal of Pharmacy, Medical and Health Science by https://journal.unsika.ac.id/ is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
You are free to:
- Share, copy and redistribute the material in any medium or format
- Adapt, remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
References
Unger, T., Borghi, C., Charchar, F., Khan, N. A. & Poulter, N. R. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension 75, 1334–1357 (2020).
Pemerintah Provinsi Lampung Dinas Kesehatan. Profil Kesehatan Provinsi Lampung Tahun 2020. (Dinas Kesehatan Lampung, 2021).
Kadir, A. Hubungan Patofisiologi Hipertensi dan Hipertensi Renal. Jurnal Ilmiah Kedokteran 5, 15–25 (2016).
Indonesia Renal Registry (IRR). 11 th Report Of Indonesian Renal Registry 2018. Indonesia Renal Registry (2018).
Riannur, T., Syamsul, E. S. & Sentat, T. Analisis biaya minimal Candesartan dibandingkan Amlodipin pada pasien hipertensi rawat jalan di RS ‘X’ Kota Samarinda. Prosiding Seminar Nasional Kesehatan 1, 94–103 (2021).
Faramitha, A., Prihartanto, B. & Destiani, D. P. Analisis Minimalisasi Biaya Terapi Antihipertensi dengan Kaptopril-Hidroklorotiazid dan Amlodipin-Hidroklorotiazid di Salah Satu Rumah Sakit Kota Bandung. Indonesian Journal of Clinical Pharmacy 6, 220–230 (2017).
Inrig, J. K. Intradialytic Hypertension: A Less-Recognized Cardiovascular Complication of Hemodialysis. YAJKD 55, 580–589 (2010).
Pahlawan, M. K., Astri, Y. & Saleh, I. Penggunaan Obat Antihipertensi pada Pasien Hipertensi di Bagian Rawat Jalan RS Muhammadiyah Palembang Periode Juli 2011-Juni 2012. Syifa Medika 4, (2013).
Rahmawati, C. & Nurwahyuni, A. Analisis Minimalisasi Biaya Obat Antihipertensi antara Kombinasi Ramipril-Spironolakton dengan Valsartan pada Pasien Gagal Jantung Kongestif di Rumah Sakit Pemerintah XY di Jakarta Tahun 2014. Jurnal Ekonomi Kesehatan Indonesia 1, (2017).
Untari, E. K., Kurniawan, H. & Maymuna, E. Risiko Kejadian Batuk Kering Pada Pasien Hipertensi Yang Menggunakan ACEI Dan Upaya Penanganannya. Jurnal Mahasiswa Farmasi Fakultas Kedokteran UNTAN 5, (2021).
Direktorat Jenderal Pelayanan Kesehatan. Profile Fasyankes RSUD Dr. H. Abdul Moeloek. Kementerian Kesehatan Republik Indonesia (2022).
Mustika, F. Audit Sistem Informasi Rumah Sakit Umum Daerah Dr. H. Abdul Moeloek Provinsi Lampung Ruang Mawar. IBI Darmajaya (2020).
Purwidyaningrum, I., Istiqomah & Sunarni, T. Analisis Biaya Riil Pengobatan Pasien Hipertensi Rawat Inap Terhadap Tarif INA-CBG’s Di RSNU Jombang. Medical Sains : Jurnal Ilmiah Kefarmasian 7, (2022).
Lakoan, M. R., Andayani, T. M. & W, C. Analisis Kesesuaian Biaya Rill Terhadap Tarif INA-CBG’s Pada Pengobatan Gagal Jantung Kongestif Pasien JKN Rawat Inap RSUD Dr. Soehadi Prijonegoro Sragen Tahun 2015. Jurnal Farmasi & Sains Indonesia, Desember 2, (2019).
Nisa, B. I. & Raharjo, B. B. Determinan Selisih Biaya Riil dan Tarif INA CBG’s pada Pasien Jantung Koroner. Higeia Journal Of Public Health Research And Development 5, (2021).
Amaliah, L. & Richana, R. Pengaruh Kegiatan Konsultasi Terhadap Tingkat Kecemasan Pada Keluarga Pasien Yang Dirawat Di Ruang ICU RSUD Waled Kabupaten Cirebon. Jurnal Kesehatan Mahardika 5, (2018).
Mamengko, D. M., Tasik, F. & Rares, J. J. Kualitas Pelayanan Instalasi Gawat Darurat Di Rumah Sakit Umum Pusat Prof. Dr. R. D. Kandou Manado. Jurnal Transdisiplin Pertanian 5, 549–560 (2021).
Azalea, M., Andayani, T. M. & Satibi. Analisis Biaya Pengobatan Penyakit Ginjal Kronis Rawat Inap Dengan Hemodialisis Di Rumah Sakit. Jurnal Manajemen dan Pelayanan Farmasi 6, (2016).
Jurana. Analisis Minimalisasi Biaya (Cost Minimization Analysis) Penggunaan Antibiotik Pada Terapi Demam Tifoid. (UIN Alauddin, 2018).
Mohd Razali, N. & Bee Wah, Y. Power Comparisons of Shapiro-Wilk, Kolmogorov-Smirnov, Lilliefors and Anderson-Darling tests. Journal of Statistical Modeling and Analytics 2, 13–14 (2011).
Untari, E. K., Kurniawan, H. & Maymuna, E. Risiko Kejadian Batuk Kering Pada Pasien Hipertensi Yang Menggunakan ACEI Dan Upaya Penanganannya. Jurnal Mahasiswa Farmasi Fakultas Kedokteran UNTAN 5, (2021).
Putri, S. A., Ramdini, D. A. & Wardhana, M. F. Literatur Review: Efek Samping Penggunaan Obat Hipertensi. Jurnal Medula 13, (2023).
Pratiwi, E. A., Qiyaam, N., Nurbaerty, B. & Rahmawati, C. Analisis Biaya Langsung Medis kombinasi Ramipril dan kombinasi Candesartan Pada Pasien Rawat Inap Gagal Jantung Kongestif dii RSUD Provinsi NTB Tahun 2018. (Universitas Muhammadiyah Mataram, 2019).
Nurfitri, S. Analisis Minimalisasi Biaya Penggunaan Antihipertensi Kaptopril dibandingkan Kandesartan pada Terapi Hipertensi Esensial di Rumah Sakit Ibu dan Anak Keluarga Kita Tangerang Tahun 2017. (UPN Veteran Jakarta, 2019).